Evidence map›Paper›PMID 41818928›Full record

ArticleOral oncology2026

Sex-based immune differences influence tumor progression in head and neck squamous cell carcinoma.

Sushmitha Jagadeesha, Felipe Lamenza, Puja Upadhaya, Catherine Chung, Amy Webb, Kishan Nyati, Ravi Ramalingam, Suvekshya Shrestha, Shaheer Masood, Sonali Dasari and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oral oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sushmitha JagadeeshaDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Felipe LamenzaDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Puja UpadhayaDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Catherine ChungDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Amy WebbDepartment of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.
Kishan NyatiDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Ravi RamalingamDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Suvekshya ShresthaDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Shaheer MasoodDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Sonali DasariDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Natalie KazmierowiczDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Steve OghumuDepartment of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Electronic address: Oghumu.1@osu.edu.

Funding

X chromosome inactivation in sex disparities to substance use disorderDP1DA054344 · NIDA · OHIO STATE UNIVERSITY · PI Steve Onyeka Oghumu · 2021 to 2026
$2.4M
The oral glucocorticoid system in oral carcinogenesis and its modulation for improved treatment outcomesR01DE033906 · NIDCR · OHIO STATE UNIVERSITY · PI Steve Onyeka Oghumu · 2024 to 2026
$1.9M
NIDA NIH HHS DP1 DA054344NIDCR NIH HHS R01 DE033906
6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) presents with higher incidence and poorer prognosis in males compared to females, yet the mechanisms underlying this sex disparity remains unclear. We investigated whether sex-specific immune responses contribute to differential tumor control using syngeneic and oral carcinogen-induced HNSCC mouse models., Female mice exhibited significantly reduced tumor burden, delayed progression and decreased metastatic potential compared to males. Immune profiling revealed a more robust antitumor immune landscape in females, characterized by heightened effector T cell activation, increased production of pro-inflammatory cytokines (IFN-γ, TNF-α), reduced expression of T cell exhaustion markers (PD-1, TIGIT), and a lower frequency of immunosuppressive myeloid-derived suppressor cells. Importantly, CD8

Indexed as

Head and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckAnimalsCD8-Positive T-LymphocytesCytokinesDisease ProgressionFemaleMaleMiceMice, Inbred C57BLSex CharacteristicsSex FactorsT-Cell ExhaustionCytokinesCD8(+) T cellsEffector T cell functionHead and Neck Squamous Cell CarcinomaSex differences

Identifiers

PMID41818928
PMCPMC13075524

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.